Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend

ADC Therapeutics SA

10/03/2026 11:39

Overview

Swiss antibody drug conjugate firm's Q4 net income beat analyst expectations

Q4 net product revenue rose to $22.3 mln, driven by stable demand and higher prices

Company amended HealthCare Royalty financing for greater strategic flexibility

Outlook

Company anticipates cash runway extending into 2028

Result Drivers

REVENUE GROWTH - Q4 net product revenue increased due to stable demand and higher prices

R&D EXPENSES - Decrease in R&D expenses due to reduced spending on discontinued programs and completion of certain activities

STRATEGIC FLEXIBILITY - Amended HealthCare Royalty financing agreement enhances strategic flexibility

Company press release: ID:nPn9PTGXxa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
Beat
-$6.41 mln
-$37.65 mln (6 Analysts)
Q4 Income from Operations
Beat
-$17.92 mln
-$30.08 mln (6 Analysts)
Q4 Basic EPS
-$0.04
Q4 Operating Expenses
-$40.98 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for ADC Therapeutics SA is $8.00, about 89.1% above its March 9 closing price of $4.23

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)